Risk of Cardiac Arrhythmias Among Climbers on Mount Everest.

Sherpa, Kunjang; Sherpa, Pasang Phurba; Sherpa, Tendi; Rothenbühler, Martina; Ryffel, Christoph; Sherpa, Dhukpa; Sherpa, Dawa Renji; Sherchand, Ojaswee; Galuszka, Oskar; Dernektsi, Chrisoula; Reichlin, Tobias; Pilgrim, Thomas (2024). Risk of Cardiac Arrhythmias Among Climbers on Mount Everest. JAMA cardiology, 9(5), pp. 480-485. American Medical Association 10.1001/jamacardio.2024.0364

Text jamacardiology_sherpa_2024_br_240002_1710776582.63525.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (255kB)

IMPORTANCE

Arterial hypoxemia, electrolyte imbalances, and periodic breathing increase the vulnerability to cardiac arrhythmia at altitude.

OBJECTIVE

To explore the incidence of tachyarrhythmias and bradyarrhythmias in healthy individuals at high altitudes.

DESIGN, SETTING, AND PARTICIPANTS

This prospective cohort study involved healthy individuals at altitude (8849 m) on Mount Everest, Nepal. Recruitment occurred from January 25 to May 9, 2023, and data analysis took place from June to July 2023.

EXPOSURE

All study participants underwent 12-lead electrocardiogram, transthoracic echocardiography, and exercise stress testing before and ambulatory rhythm recording both before and during the expedition.

MAIN OUTCOME

The incidence of a composite of supraventricular (>30 seconds) and ventricular (>3 beats) tachyarrhythmia and bradyarrhythmia (sinoatrial arrest, second- or third-degree atrioventricular block).

RESULTS

Of the 41 individuals recruited, 100% were male, and the mean (SD) age was 33.6 (8.9) years. On baseline investigations, there were no signs of exertional ischemia, wall motion abnormality, or cardiac arrhythmia in any of the participants. Among 34 individuals reaching basecamp at 5300 m, 32 participants climbed to 7900 m or higher, and 14 reached the summit of Mount Everest. A total of 45 primary end point-relevant events were recorded in 13 individuals (38.2%). Forty-three bradyarrhythmic events were documented in 13 individuals (38.2%) and 2 ventricular tachycardias in 2 individuals (5.9%). Nine arrhythmias (20%) in 5 participants occurred when climbers were using supplemental bottled oxygen, whereas 36 events (80%) in 11 participants occurred at lower altitudes when no supplemental bottled oxygen was used. The proportion of individuals with arrhythmia remained stable across levels of increasing altitude, while event rates per 24 hours numerically increased between 5300 m (0.16 per 24 hours) and 7300 m (0.37 per 24 hours) before decreasing again at higher altitudes, where supplemental oxygen was used. None of the study participants reported dizziness or syncope.

CONCLUSION AND RELEVANCE

In this study, more than 1 in 3 healthy individuals experienced cardiac arrhythmia during the climb of Mount Everest, thereby confirming the association between exposure to high altitude and incidence of cardiac arrhythmia. Future studies should explore the potential implications of these rhythm disturbances.

Interest & Impact

Downloads

0 since deposited on 04 Apr 2024
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item